Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harshil Dhruv

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Journal of Biological Chemistry|September 24, 2013
Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosisHarshil Dhruv, Joseph C Loftus, Pooja Narang, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2025
Overcoming CK1α liability in the discovery of a series of isoIndolinone Glutarimides as selective IKZF2 molecular glue degradersXuqing Zhang, Qiaolin Deng, Harshil Dhruv, et al.
Neuro-Oncology|December 10, 2016
Integrated genomic analysis of survival outliers in glioblastomaSen Peng, Harshil Dhruv, Brock Armstrong, et al.
International Journal of Cancer|March 31, 2011
MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migrationShilpi Arora, Aarati R Ranade, Nhan L Tran, et al.
Journal of Medicinal Chemistry|August 22, 2025
Discovery of a Novel Series of <i>iso</i>-Indolinone-Based Glutarimides as Highly Efficacious and Selective IKZF2 Molecular Glue DegradersXuqing Zhang, Harshil Dhruv, Qiaolin Deng, et al.
Nature Communications|May 1, 2025
Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapyZhixiang Chen, Harshil Dhruv, Xuqing Zhang, et al.
Neuro-Oncology Advances|August 4, 2020
Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progressionMylan R Blomquist, Shannon Fortin Ensign, Fulvio D'Angelo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERTManmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Journal of Biological Chemistry|September 24, 2013
Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosisHarshil Dhruv, Joseph C Loftus, Pooja Narang, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2025
Overcoming CK1α liability in the discovery of a series of isoIndolinone Glutarimides as selective IKZF2 molecular glue degradersXuqing Zhang, Qiaolin Deng, Harshil Dhruv, et al.
Neuro-Oncology|December 10, 2016
Integrated genomic analysis of survival outliers in glioblastomaSen Peng, Harshil Dhruv, Brock Armstrong, et al.
International Journal of Cancer|March 31, 2011
MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migrationShilpi Arora, Aarati R Ranade, Nhan L Tran, et al.
Journal of Medicinal Chemistry|August 22, 2025
Discovery of a Novel Series of <i>iso</i>-Indolinone-Based Glutarimides as Highly Efficacious and Selective IKZF2 Molecular Glue DegradersXuqing Zhang, Harshil Dhruv, Qiaolin Deng, et al.
Nature Communications|May 1, 2025
Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapyZhixiang Chen, Harshil Dhruv, Xuqing Zhang, et al.
Neuro-Oncology Advances|August 4, 2020
Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progressionMylan R Blomquist, Shannon Fortin Ensign, Fulvio D'Angelo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERTManmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz, et al.
Pageof 2